- Report
- January 2024
- 200 Pages
Global
From €4808EUR$5,000USD£4,124GBP
- Report
- March 2024
- 145 Pages
Global
From €3749EUR$3,899USD£3,216GBP
- Report
- January 2024
- 395 Pages
Global
From €7212EUR$7,500USD£6,187GBP
- Report
- August 2022
- 117 Pages
Global
From €4327EUR$4,500USD£3,712GBP
- Report
- February 2024
- 227 Pages
China
From €3846EUR$4,000USD£3,299GBP
- Report
- February 2024
- 114 Pages
China
From €1731EUR$1,800USD£1,485GBP
- Report
- May 2024
- 50 Pages
Global
From €2548EUR$2,650USD£2,186GBP
- Report
- May 2024
- 50 Pages
Global
From €2548EUR$2,650USD£2,186GBP
- Report
- March 2022
Global
From €4663EUR$4,850USD£4,001GBP
- Report
- March 2021
Japan, United States, ... Japan, United States, Europe
From €913EUR$950USD£784GBP
- Report
- February 2020
Japan, United States, ... Japan, United States, Europe
From €913EUR$950USD£784GBP
- Report
- September 2019
Global
From €5163EUR$5,370USD£4,430GBP
- Report
- January 2022
- 137 Pages
Global
From €4327EUR$4,500USD£3,712GBP
- Book
- July 2009
- 1116 Pages
Phenobarbital is a central nervous system drug used to treat seizures and insomnia. It is a barbiturate, a type of drug that acts as a sedative-hypnotic. It is also used to treat alcohol withdrawal and to prevent seizures in people with epilepsy. Phenobarbital is available in both generic and brand-name forms. It is typically taken orally, but can also be administered intravenously. Common side effects include drowsiness, dizziness, and confusion.
Phenobarbital is one of the oldest and most widely used anticonvulsant drugs. It is used to treat a variety of seizure disorders, including generalized tonic-clonic seizures, partial seizures, and status epilepticus. It is also used to treat insomnia and alcohol withdrawal.
The phenobarbital market is a part of the larger central nervous system drugs market. This market is driven by the increasing prevalence of neurological disorders, such as epilepsy, Alzheimer's disease, and Parkinson's disease. The market is also driven by the increasing demand for generic drugs, as well as the development of new drugs to treat neurological disorders.
Some companies in the phenobarbital market include Pfizer, GlaxoSmithKline, Sanofi, Novartis, and Mylan. Show Less Read more